Back to Dashboard

NASDAQ:VRTX

VERTEX PHARMACEUTICALS INC / MA

United StatesConsumerPharmaceutical PreparationsNasdaq
542.5
USD · Close 5 Nov 2026

Intrinsic value vs last close

Model estimate
Close above intrinsic value
−32.2%Intrinsic value vs last close
At last close+500%
Last close (USD)
542.50
Intrinsic value (USD)
367.91

Intrinsic value = sector model's value (no adjustment)

Earnings-capitalised value

197.44−63.6%vs last close

Cost of equity 11.9% · price volatility 29.5%

Last year's earnings per share, capitalised at a cost of equity that rises with this share's own price swings, growing at the sector's long-run rate.

This is a different figure from the intrinsic value above. The intrinsic value is what the sector model says the business is worth. On Vietnamese stocks this figure has ranked future returns best in our track record; this market has no track record here yet.

Model reliability
Medium
Model fitInput stabilityRisk checks
High requires the model’s diagnostic criteria to be met.
Probability of outperforming peers
Not assessed
A separate peer-outperformance probability is unavailable for this valuation.
Assessed 5 Nov 2026Not updated with daily prices

These assessments address different questions. Neither establishes that the displayed valuation is correct or guarantees a future return.

Valuation Breakdown

Pharmaceutical Preparations→Consumer
Classified as consumer from the industry its market data reports: “Pharmaceutical Preparations”.
ModelFCF-Based DCF
Intrinsic = 70% x DCF Value + 30% x (Fair P/E x EPS)

A Discounted Cash Flow model built on Free Cash Flow (FCF), the cash a business generates after operating expenses and capital expenditures. Future FCF is projected for 10 years with gradually decaying growth, then discounted to today's value using WACC. The DCF value is blended 70/30 with a value from the company's own historical P/E.

Technical details
Why this model

Consumer staples/retail generate steady, predictable free cash flows, making them ideal for DCF. The time value of money principle means a dollar today is worth more than a dollar tomorrow. DCF captures this by discounting future cash flows at a rate reflecting the investment's risk (WACC).

How it works

Takes 3-year median FCF as the base. Estimates growth via ROIC x reinvestment rate (Damodaran framework), falling back to historical revenue growth. Projects 10 years with decay toward the sector's long-run growth rate. Discounts at CAPM-derived WACC. Blends 70% of the DCF value with 30% of a P/E value: the company's 5-year median P/E, held between 5x and 25x, times EPS.

Best for

Stable consumer businesses (food, beverage, retail, healthcare) with predictable, positive free cash flows.

1
Weighted Avg Cost of Capital
Risk-Free (Rf)
4.94%
+
Betasector default
0.714
x
ERP
4.20%
+
CRP
0.22%
=
Cost of Equity (Ke)
8.16%
Ke
8.16%
x
E/(D+E)
100.00%
+
Kd(1-t)
0.00%
x
D/(D+E)
0.00%
=
WACC
8.16%
2
Growth Estimate
fundamental firm blend8.00%
Growth decays 10%/yr toward terminal
3
Model Inputs
Base FCF→3.20B
Projection years→10
4
Valuation

We compare the sector model's value with the last close. This market has no track record here yet, so the value is shown as the model gives it.

Last close (USD)→542.50
Intrinsic value vs last close→−32.2%

Intrinsic value = sector model's value (no adjustment)

Intrinsic value (USD)
367.91
What feeds each step— click a source to highlight it in the statements
Discount rate (WACC)8.16%
Growth rate8.00%growth method: fundamental firm blend
Base cash flow3.2Bone off strip ratio: 0

DCF Sensitivity

Values from the standalone DCF scenarios below. These scenarios leave out the other parts of a blended model and do not reproduce the headline value.

WACC \ Growth5.0%6.5%8.0%9.5%11.0%
6.2%624.65654.31697.32751.12815.17
7.2%429.21449.22478.01513.77556.12
8.2%327.73342.74364.16390.60421.74
9.2%265.58277.54294.45315.22339.55
10.2%223.62233.51247.40264.35284.11
Above market priceBelow market priceCurrent estimate
Feeds valuation:Cost of capitalGrowthModel inputsFinal calculation
Line item20262025202420232022202120202019201820172016201520142013201220112010200920082007
Cash and cash equivalentsNet debt bridge
·5,0854,57010,36910,5046,7955,9883,1092,6501,6651,184715625569489475243447389356
Short-term investmentsNet debt bridge
·1,5231,546849275730671699518···········
Inventories, Net
·1,6871,2057394613532811681241127857311430112····
Fixed assets
········7587896986987166974341337262··
TOTAL ASSETS
·25,64322,53322,73018,15113,43311,7528,3186,2623,5592,8972,4992,3352,3192,7592,2041,7251,955··
OWNER'S EQUITYDiscount rate (WACC)
·18,66616,41017,58013,91310,1008,6876,0854,4352,0421,3381,0941,0961,3561,1969285041,096239271
MINORITY INTERESTSNet debt bridge
········0.0014182154210.00197142····

Earnings Quality

Fiscal year 2025
71
Good
Accrual Quality
95
Cash Conversion
74
Margin Stability
0
Revenue Quality
100

Quantitative Scores

F-Score
5/9
Neutral
Sharpe
0.72
Positive
Composite
48
30 to 49
Piotroski F-Score Breakdown
✓Net Income > 0
✓Operating CF > 0
✓ROA Rising
✗OCF > Net Income
✓Lower Leverage
✗Better Liquidity
✓No Dilution
✗Margin Up
✗Turnover Up
Price Risk
Momentum
+19.9%
Volatility
29.9%
Max Drawdown
−15.2%

Key Ratios

Fiscal year 2025
34.70P/E
P/B
7.35
P/S
11.43
ROE
21.2%
EPS
15.46
BVPS
73.00
Net Margin
32.9%
D/E
0.00
Rev Growth
+8.9%
EV/EBITDA
29.79
Div Yield
—

Company Overview

Shares outstanding
254M
Industry
Pharmaceutical Preparations
Computed 05/11/2026
Methodology & Disclosure

vnvalue is a stock research tool. Its results are calculated from public financial data with published formulas. Nothing on this page constitutes investment, financial, legal, or tax advice, nor a recommendation to buy, sell, or hold any security.

All data, models, and outputs are provided AS IS without warranty of any kind. You are solely responsible for your investment decisions. Past performance and historical valuations are not indicative of future results.

By using vnvalue you accept the Terms of Service and Privacy Policy. Full disclaimer →